Facebook Linkedin Tumblr Twitter
Home Blog Page 14620

Five Small Caps That Shouldn’t Be Small Caps

By
ME Staff
-
small caps

Markets are continuing to struggle in the wake of last week’s decline. After a tepid recovery, it looks as though the major indices have returned to an overarching bearish trend, as investors rush to reduce exposure to their more risky assets. What better time, then, to try and find some hidden gems. Here are five fundamentally sound small caps with little or no analyst coverage that look undervalued at current prices.

Enzymotec Ltd. (NASDAQ:ENZY)

First up we’ve got Enzymotec. This company produces a range of pharmaceutical foods that it sells globally. In the US, its products fall under the medical foods category (regulated by the FDA) and outside the US it forms partnerships with pharmaceutical companies and licenses its products for resale. Its portfolio includes food based treatments for ADHD, elevated triglyceride levels (an early onset symptom of heart disease) and memory impairment. Based in Israel, the beauty of this company is its current market capitalization. The market values Enzymotec at a little over $235 million – despite average annual revenues over the past three years of circa $50 million and 2014 net income of $7.8 million. With a trailing 12-month (ttm) price/sales of 5.23, and a forward P/E of 19.44, alongside just short of $40 million cash and cash equivalents and no debt, this is a real fundamentally sound operation.

EMCORE Corporation (NASDAQ:EMKR)

Here is one of that might be controversial. EMCORE fell from grace spectacularly following 2008, having peaked out around $60 a share now trades for just $6.80. However, and despite a number of institutional selloffs over the last month or so, the company reported Q3 revenues of $21.2 million and GAAP net income of $2.4 million. Further, it completed a Dutch auction buy back of $45 million worth of shares of its own common stock back in June. Operationally the company builds and provides raw materials for semiconductor systems and the fibre optics market. Annual revenues came in at $174 million last year – bang on its current market capitalization. Price/sales (ttm) comes in at just 0.92, and once again, with more than $140 million cash and cash equivalents and zero debt, the company looks well set to expand its bottom line going forward. The next big release will be its 2015 year-end, which we should get in October (year-end to September for this company).

Perion Network Ltd. (NASDAQ:PERI)

Another one based out of Israel, Perion is a data company that provides analytics primarily for the mobile advertising space. The company posted second-quarter net income of a little over $8 million at the beginning of this month on revenues of $48.6 million. Annual revenues are forecast at just shy of $200 million for FY 2015. Despite this, the company’s market capitalization is just $169 million, currently trading for just $2.30 a share. The mobile advertising industry is set to expand to just shy of $60 billion by 2017, and Perion looks well placed to take advantage of this growth. The company has some debt on its books – circa $40 million. However, with cash and cash equivalents of hundred and $27.9 million translating to a current ratio of 2.92, operational spend shouldn’t be a near-term problem.

Bellatrix Exploration Ltd. (NYSE:BXE)

Alongside the majority of the oil and gas industry, Bellatrix has suffered over the past few years – at least as far as the equities markets are concerned. Having reached nearly $10 a share in early 2014, the company has since collapsed to trade just shy of two dollars a share at last close. On revenues of $72.3 million during Q2 2015, the company reported a loss of $19.9 million – likely as a result of the decline in the price of natural gas. Additionally, the company is highly leveraged, with more than $500 million debt versus cash and cash equivalents of $7.7 million. However, with the pending interest rate hike at US, we could well see a turnaround in commodities prices. If this happens, oil and gas companies trading for less than five times revenues will be tough to find. A little more risky than some of the others, this one, but worth a look nonetheless.

Genco Shipping & Trading Ltd. (NYSE:GNK)

Finally we have Genco. Genco is a New York head quartered company that ships commodities and dry-load cargo globally. The company up listed to the NYSE mid-July and having debuted around $7.6 a share, currently trades for $5.4 – a 25% discount on its up listing price. The decline comes on recent earnings that revealed a net loss for Q2 2015 at just over $40 million on revs of $34.6 million. However, analysts forecast annual revenues of $234 million this year, and an improved dryload environment should feed into this expansion. Further, a recently completed merger with competitor Baltic Trading should help to consolidate costs and streamline operations going forward. With this said, this one really is an asset value play. The company has vessel assets of more than $1.2 billion, and current liabilities of just $63 million. In other words, its share price is diminished through overarching industry decline, but if it can ride out the storm, it could be set for a rapid revaluation.

Story continues below

Allergan Announces Game Changer for Avycaz

By
Jennifer Aldershot
-
allergan

A few hours ago, Allergan plc (NYSE:AGN) hit markets with the latest results from a phase 3 study of AVYCAZ – it’s antibiotic treatment targeting complicated urinary tract infections (cUTI). The FDA approved the treatment way back in February this year, but – due to a lack of safety and efficacy data – only approved it for patients that have not responded to all other treatment alternatives. This limiting factor reduced the potential patient pool considerably, and in an attempt to widen the indication, Allergan teamed up with AstraZeneca PLC (NYSE:AZN) to conduct further trials. These trials – RECAPTURE 1 and RECAPTURE 2 – focused solely on safety and efficacy, and from both the perspective of the FDA and the EMA were considered as one individual trial. The goal now is for a supplemental new drug application (sNDA) to head towards both regulatory authorities, and get the indication widened. So, what’s next?

First, let’s have a quick look at the drug itself. The drug is a combination of two elements – ceftazidime and avibactam. The former is a widely used and already well-established antibiotic used to target gram-negative bacteria. These types of bacteria cause some of the most serious infections – primarily as a result of their impenetrable cell wall making them hard to treat and prone to antibiotic resistance. They produce what’s called lactamase, which is an enzyme that breaks down antibiotic treatments. This breaking down is at the core of antibiotic resistance, and at the root of AVYCAZ’s efficacy. Avibactam is a lactamase inhibitor, meaning it protects the ceftazidime antibiotic from the lactamase. In doing so, it makes the bacteria no longer resistant to the ceftazidime antibiotic – ergo sum, increased efficacy. The treatment acheived accelerated review, but as part of this acceleration and approval there was not enough safety and tolerability data available to approve it across a wide indication. Alongside the FDA approval announcement, we got this statement:

“It is important that the use of AVYCAZ be reserved to situations when there are limited or no alternative antibacterial drugs for treating a patient’s infection.”

With the announcing of the RECAPTURE trial results, it looks as though this limited indication is about to expand. The trial compared AVYCAZ to a placebo arm across than 1000 hospitalized cUTI patients in 30 countries. The FDA and the EMA had two separate definitions of success across the trial, but both definitions were met and proven as being statistically significant.

David Nicholson, Executive Vice President & President, Global Brands R&D at Allergan, had this to say alongside the announcement:

“We are very pleased by these results, which we plan to submit to the FDA to further support the use of AVYCAZ as a treatment option for patients with these serious and life-threatening complicated urinary tract infections.”

So what’s next? Well, now comes the sNDA. The FDA will accept the supplementary documents and take into consideration the updated results when considering an expansion of the treatment’s potential indications. The key thing here is that safety and tolerability were what both arms of the trial focused on, and with these met, it is difficult to see why the FDA wouldn’t expand the treatment’s indication. Especially when the lack of data to support these two elements of the approval were what restricted it in the first place. It goes without saying that nothing is guaranteed, but markets will likely price in this extended approval going forward in advance of its announcement.

Despite the positive release, Allergen is trading slightly down for the day, while Astrazeneca is up 2.5% at time of writing.

Story continues below

Another Rocky Day for Stocks as Crude Inventories and Beige Book on Deck

By
TradeCircle
-
Beige Book

Here we go again with the ups and downs. All major indexes opened the day with a sharp gap down, the fall continuing until the final 14 minutes of trading. Since breaking support at 2040 two weeks ago, the S&P 500 (^GSPC) has consistently had a flourish of volatility in the final hour of trading or so.

We saw it on Thursday, August 27th, with stocks moving 2% in less than an hour into the close. On Wednesday, they moved up 2.3% in an hour and forty minutes. The day before, the index fell 3% in an hour, the Dow Jones (^DJI) had fallen 3.2%. Very large players seem to be making very large trades at the close lately.

Even the calmer days have looked more like jagged mountain ranges, with even small changes taking very large slopes in either direction.

Oil (NYSEARCA:USO) keeps rising and falling as if in hysterics. One of the few assets rising with any sort of calm regularity has been gold (NYSEARCA:GLD), sneaking its way up another 0.35% today as if nothing out of the ordinary is going on at all.

Tomorrow could be even more volatile for oil, as the nearly schizophrenic commodity will certainly respond to the crude inventories report, scheduled for release at 10:30AM EST. This will be followed three and a half hours later by the Fed’s Beige Book, which will give a basic summary of economic conditions over the last of the last six and a half weeks.

All of this is noise, and investors should expect the volatile whipsawing action to continue until the Fed makes a decision on whether or not to raise rates. The best indication of what they will do on that front will be the unemployment numbers for August, to be released on Friday morning, September 4 at 8:30AM.

Any number below 5.3% will increase the chances of a rate hike, so don’t be surprised if the market reacts negatively to low unemployment numbers. It will look strange, but there is a method to this madness. Just keep holding on to your hats.

Story continues below

Biotech 101: Drug Development and the FDA

By
Jennifer Aldershot
-
NDA

Investing in biotech is unlike investing in any other sector of the market. Much of the time, investors will look to take a position in companies that aren’t yet generating revenues, but have drugs or therapies in development. Instead of earnings and sales driving the valuation, therefore, markets must look to the development process of the therapies in question. You can think of clinical trials as milestones in a new drug development process – they follow a set pattern, a relatively similar structure across therapies and the company must successfully complete one before moving onto the next. As development stage biotech investors, it’s important to understand what the completion of each stage means for a treatment’s prospects. So, with this said, let’s take a look.

Discovery and Preclinical

Everything kicks off with the discovery phase. Discovery is ongoing, and more often than not takes place in University or College research laboratories. During discovery, scientists test thousands and thousands of compounds each year in order to ascertain whether any are worth carrying forward into development. The vast majority of those tested go no further.

The small number that do pass discovery go in to what’s called preclinical testing. Essentially, this is testing on animals (often mice or primates) in order to gauge the safety of a compound. It is worth mentioning that efficacy isn’t really under scrutiny here and – as a result – few investors get excited about preclinical testing. Next up is where the real action begins.

Trials Begin

Phase 1 trials are for those compounds that have shown the potential for efficacy in discovery and proven they are safe enough to be administered in humans – albeit a small sample. It is not unusual for phase 1 trials to consist of a single or low double-digit sample size, but they can run up to a maximum of triple digits for a treatment with a potentially large-scale application. Once again, here, efficacy is not that important. When things reach this stage, the company developing the treatment will set “endpoints” – generally primary and secondary. Primary is the main goal of the trial, while secondary are extended (but often less important) goals. The primary endpoints of phase 1 trials and generally safety and tolerability. Simply put, the company is looking to confirm the conclusion of the preclinical safety data, while establishing a tolerability level – or dose, in other words. Efficacy is often no more than a secondary endpoint at this stage.

If the treatment is successful in its phase 1 trials (i.e. it meets its primary endpoint) it will generally then head into phase 2. The aim of a phase 2 trial is to show the treatment is effective across a reasonably sized sample. There is no set number associated with the sample size, but they normally involve triple digits, with the general rule being the more common the targeted indication that higher the sample size. Once again, the developing company will set primary and secondary endpoints before heading into trial – with the primary being a specific efficacy endpoint related to a predefined marker. The market varies depending on the nature of the indication. For example, for this phase 2 trial of AstraZeneca PLC’s (NYSE:AZN) glioblastoma treatment MEDI4736, the primary endpoint was efficacy as judged by overall survival rate at 12 months. What this means is if at 12 months the rate of survival is higher in patients treated with MEDI4736 than those not, the trial has met its primary endpoint.

Finally, if a treatment is successful in phase 2, it will head onto a phase 3 trial – the final phase of the process before the company is able to file a new drug application (NDA) the FDA. More often than not, the primary and secondary endpoints in a phase 3 trial are similar if not identical to those in the phase 2, but the goal is to replicate phase 2 results across a much wider sample size. In a common indication, the sample can range up to thousands. In an ongoing Alzheimer’s trial conducted by Biogen Inc. (NASDAQ:BIIB), for example, Aducanumab will be administered to an estimated to 2700 patients across a period of five years. Delivering a drug on this scale also forces the company to prove that it can manufacture and distribute a treatment safely and effectively if required as part of a post approval, scaled up, administration regime.

NDA Submission

Between 25 and 30% of phase 3 drugs demonstrate efficacy across a wide scale population, and become eligible for submission as part of a NDA. Essentially this is where the company brings together everything it has learnt and proven about the treatment in question, and submits it for consideration by the FDA.

The remit of a successful NDA is that it must allow the FDA to answer three questions concerning the treatment. First, is the drug is safe and effective (also, does its benefits outweigh its risks?). Second, does the drug’s packaging clearly display the information patients and consumers require to make informed decisions? Third, can the company in question manufacture the drug and distribute it without interfering with safety and efficacy demonstrated at small scale administration?

If the answer to any of these questions is no, the FDA will generally return the NDA to the development company to request revisions – either that or decline the drug outright. However, if the FDA is satisfied, it will approve the drug and the development company can take the treatment forward to the marketing stage – essentially it can start to generate revenues.

A Final Consideration…

Remember, a drug’s approval does not guarantee success in the market. There have been numerous failed introductions, with one famous example being Pfizer Inc.’s (NYSE:PFE) inhalable insulin treatment Exubera. What looked like a potentially $5 billion blockbuster proved not to strike a chord with its target market and ended up costing Pfizer nearly $3 billion!

And there we have it. Aside from ongoing trials (sometimes called phase 4) that monitor a drug’s efficacy and safety for an extended period of time after the marketing phase, this pretty much sums up the development timeline. How an investor approaches each of these develop phases, and what they look for in clinical trial results releases, is something we will address in a later article. For now, however, get to grips with this structure and you will have a firm grounding in how a drug gets to market.

Image courtesy of Raymond Bryson

Story continues below

Today’s oil move could be signalling stagflation

By
TradeCircle
-
StagFlation

Today’s trading was very unique. Nevermind oil’s (NYSEARCA:USO) third consecutive day of monster gains. That is the obvious anomaly that will be pointed out by everyone. In fact, oil has had its biggest 3 day gain since August 1990 when President George H.W. Bush invaded Iraq.

What was even more interesting though is that treasuries (NYSEARCA:TLT), equities (^GSPC) and the US Dollar (NYSEARCA:UUP) all traded down together. Stocks and bonds usually trade inversely as the latter is generally considered a safety trade when stocks are tanking. And on the rare occasions when they do trade down together, the dollar usually still climbs, as that is another alternative safety net when both stocks and bonds are down in the same day.

Very rarely are all three moving down together.

This could be a one-off thing, but if it continues, it is a signal of stagflation. Stagflation is when the entire Keynesian system of lowering interest rates in order to stimulate economic growth is flipped on its head. It is a combination of high inflation with recession, and it only happened once for any sustained period during the mid 1970’s, particularly during the oil embargo of 1973.

If the dollar, bonds, and stocks are headed down together while oil and commodities are moving up (the entire commodity complex moved up together with oil today) then this means that the dollar is losing purchasing power, interest rates are rising, the stock market is falling, and the cost of living is going up. Hence stagnation plus inflation, or stagflation.

In the current environment, it is generally considered a good thing and a sign of economic growth when the price of oil rises. It implies there is a higher demand for oil and hence a growing economy. But the other factor that can cause a rise in oil prices is simply a fall in the purchasing power of the dollar, or in other words a fall in the demand to hold cash as cash.

If the rise in commodity prices is being fueled by higher demand, then that would mean economic growth. But if it is only being fueled by a falling dollar, then it means stagflation.

One day of trading like this is no big deal. But if it continues, big trouble could be ahead.

Story continues below

These Five Biotechs Are Undervalued

By
Roger Hannington
-
biotech

Last week’s correction has injected an element of risk off sentiment into markets, as investors attempt to reduce their exposure to any further decline. However, as a side-effect of the sell-off, there are a number of opportunities to pick up strong fundamentals at a discount. Here are five biotechs that we believe are undervalued at current prices.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

Back in June, Synergy reported the results of a phase 3 trial of its lead candidate Plecanatide. The treatment is targeted at sufferers of constipation and irritable bowel syndrome, and is a synthetic version of a peptide (a type of amino acid that forms bonds in the body) called uroguanylin. Uroguanylin is partly responsible for the amount of water that lines the gastrointestinal tract, so by introducing a synthesized version Synergy believes it can increase water flow, and normalize bowel movement. Phase 3 data illustrated efficacy, and the company hit highs of just shy of $10 in July. However, the company pushed back its approval filing from Q4 this year to Q1 next year, and this looks to have weighed on its share price a little. This said, the fundamentals remain sound, and with about $160 million cash and cash equivalents Synergy looks financially on point. Key drivers will be the two approval filings, one set for Q1 next year (as we have already mentioned) and one set for December 2016.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Next up is Oramed. Oramed hit the mainstream radar back in July when it announced the dosing of its first patient with an orally administered insulin pill. In doing so, the company proved itself as being one step ahead of Novo Nordisk A/S (NYSE:NVO), which is also developing its own version of the treatment. Since the announcement, however, Oramed stock has traded pretty flat – and is currently selling at a 75% discount on 2014 highs. While it is probably going to be 2017 before the company can get its pill into phase 3 (assuming efficacy is demonstrated in phase 2), we expect this one to gain strength between now and then. The real value in Oramed is its market potential, with best estimates putting the global insulin market at around $50 billion. The company expects to complete its ongoing phase 2 in October this year, so we will be looking for the meeting of its efficacy primary endpoint as an upside driver before the year is out.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Third on the list is Lexicon. The company rocketed into August on the announcement that its lead candidate telotristat etiprate had met its primary endpoint in a phase 3. The treatment is a combination therapy designed to work alongside current standard of care for people with carcinoid syndrome. Since the news, however, a downgrade to neutral by JP Morgan alongside a Q2 loss has discounted some of the positive momentum. The treatment has orphan and fast track, and is targeting H2 2016 as its time to market (assuming accelerated review). Lexicon’s current market cap is a little over $1.2 billion, and if it can gain approval on the recent results, it could be going after a market worth around $700 million based on price point expectations. A $300 million raise last year should see the company through to revenue generation, with the next upside driver an NDA submission before the end of January 2016.

Xenoport Inc. (NASDAQ:XNPT)

Xenoport has one treatment already generating revenues and one promising lead candidate in the pipeline. The former is a restless leg indication that generated a little over $8 million during Q2 2015 and that the company forecasts will bring in a total of $43 million before the year is out. The second is a psoriasis indication, currently undergoing phase 2. The company is currently trading around 45% from highs with a market cap of a little over $430 million – about 10 times forecast 2015 revs. The release to watch going forward on this one is the top line from the ongoing phase 2 – expected before the end of September. Interim was promising, and if we see the trial meet its primary endpoint Xenoport could be on for a quick upside revaluation. The psoriasis market will be worth $7.4 billion within five years, and we have seen comparable therapies bring in over $1 billion annually recently.

Omeros Corporation (NASDAQ:OMER)

Finally we’ve got Omeros. Having spent most of 2015 slowly ranging downwards, Omeros stock pretty much doubled in price on the release of some positive top line data from its phase 2 thrombotic microangiopathies candidate, OMS721, this month. The gains turned out to be nothing more than a spike, however, and we are currently trading pretty much bang on prerelease levels. This one is a little riskier than some of the others on the list, as the company only has about 10 months of operational capital available to it based on current burn rate – but it generates (albeit lackluster) revs from a treatment launched in April and has just hit markets with a second indication in Europe. OMS721 is the one to watch here though. Completion is slated for December this year, and we have already seen what promising results can do to its market cap.

More from Market Exclusive:

  1. Market Wrap Up – The Cat is Dead
  2. Here’s An Opportunity To pick Up A Discount In Biotech

  3. Synthetic Biologics: A Small Company Targeting A Big Market

Story continues below

Synthetic Biologics: A Small Company Targeting A Big Market

By
Roger Hannington
-
Synthetic Biologics

US healthcare spending is a hot topic at the moment. By 2024, government spend on healthcare is expected to account for one fifth of gross domestic product – more than double that of the vast majority of other developed nations. Anything that can reduce this overspend, therefore, could be big business. One company currently working in the space, and even better, one that has a number of near-term milestones that could inject some upside potential into its market capitalization, is Synthetic Biologics Inc. (NYSE:SYN). With a market capitalization of a little over $210 million, Synthetic Biologics is a development stage pharma, but one that is tackling a potentially huge market. Let’s take a look at the company and its potential.

The company has two lead pipeline candidates, but the one that will focus on (primarily because this is the one with the near-term drivers) is SYN-004 – a preventative therapy targeted at C difficile infection, and the diarrhea and colitis associated with it. To simplify the science, C difficile is a bacterium that builds up in the gastrointestinal tract as a side effect of antibiotic treatment. Basically, a certain amount of antibiotic formula ends up in the gut (as opposed to in the bloodstream, where it belongs) and just sits there and builds up. This buildup of useless antibiotic leads to the formation of bacteria – one of which is C difficile. Every year, 14 million people receive IV antibiotics as part of surgical or other treatment in the US – with a total of 118 million administrations. Treatments targeted at C difficile buildup, and infections related, to it cost the US about $10 billion each year. At the moment, the only treatments available (and some that are in development) target the buildup. SYN-004 is preventative, designed to administer alongside an IV antibiotic treatment. Simply put, the patient takes antibiotics and SYN-004 at the same time, and the SYN-004 stops C difficile buildup without affecting antibiotic levels in the blood. At least, this is the hypothesis. So what does this mean? Well, it means that SYN-004 has the potential to treat in combination with 118 million antibiotic administrations annually. With 30,000 people dying each year from the implications of a C difficile buildup, and a potential saving of $10 billion annually, this treatment could be a real hit. That is, so long as the company can prove it is both safe and effective.

So where do we stand with that? Well, the company has initiated two phase 2A trials this year, with final data for both expected by the end of the year. Phase 1A and 1B proved safety and tolerability, as well as a certain level of efficacy on a small scale, so now we just looking at this efficacy to translate across a larger population. In anticipation of a phase 3, the company raised $42.6 million in public offering last month.

One of the great things about this area of biotech is that involves what are called microbiomes – basically just groups of microbes sealed together in a biological capsule. Why is this good? Because the time to market (i.e. the time it takes to go from preclinical to NDA) is roughly one third of the average pharmaceutical candidate. With trials well underway and fully capitalized this short time to market means a concentration of data releases – each of which have the potential to give us some upside in market cap.

So, what are we looking for over the coming few quarters? Well, the phase 2 data is expected from both A and B before the end of the year, and these releases will offer some insight into the phase 3 initiation. Management stated on last earnings call that they expect an October or November release, so we could be looking at a phase 3 initiation during the first quarter of next year. Time to completion will be about six months, so realistically, if all goes well, we could see an NDA filed way ahead of the 2017 turnaround. Looking at the trial specifically, the element to keep an eye on is the level of antibiotic in the patient’s bloodstream. If SYN-004 has any significant effect on concentration, it could seriously damage Synthetic Biologics’ chances of getting the treatment approved.

More from Market Exclusive:

  1. Market Wrap Up – The Cat is Dead
  2. Here’s An Opportunity To pick Up A Discount In Biotech

  3. AstraZeneca Might Just Have Tapped Into 90% of a $13BB Market

Story continues below

Here’s An Opportunity To pick Up A Discount In Biotech

By
ME Staff
-
biotech

There are analysts on both sides of global markets at the moment. One on side of the fence, we have those suggesting that the latest market crash is merely a correction as part of a long-term bull run, and that – as a result – it offers opportunities to get in at a discounted rate. On the other, we have suggestions that a weak economy in the US cannot withstand the proposed September interest rate hike, and further, that the crash in China that preceded the global crash came as a result of pre-emptive reduction in exposure to a Yellen hike. Regardless of which side of the fence you are on, there is one thing we can be a little more certain about – that some industries are less exposed than others. We have mentioned a couple of times already that the biotech space is one of those industries – with the demand for its products being relatively inelastic when compared to other sectors such as electronics or energy. With this in mind, here is one example of potential opportunity to get in at a discount and ride out whatever is left of this bull market on a relatively insulated exposure.

Introducing, Globus Medical, Inc. (NYSE:GMED). Globus lost nearly 18% of its market capitalization (amounting to close to $375 million) during Monday and Tuesday, and is still trading about 16% off 2015 highs – around levels that put it in line with its valuation from April or May this year. However, despite this decline, the company’s fundamentals look to be both strong and improving. On July 30, Globus reported its latest quarterly, Highlighting just short of $25 million profit on $134 million revenues – and an EPS of $.25. Based on these results, the company expects to post 2015 annual revenues of $524 million and an EPS $1.04.

So what does the company do? In short, it makes replacement robotic skeletal parts – with a particular focus on the spine. It currently has just shy of 100 unique and patented products on the market, with five of these gaining approval and reaching the market in the second quarter of this year alone. Further, there are two more products undergoing clinical trials – TRIUMPH and ACADIA – targeted at year-end completion.

So what are the downsides here? Well, the company reported in its latest earnings call that internationally it has had a pretty tough year. As yet, we’ve not seen the numbers, but they are reportedly showing marginal profitability. However, currency impacts are putting a lot of pressure on margins. If the dollar continues to strengthen (something that could well happen if Janet Yellen raises rates in September) it may be enough to turn outside US operations from black to red.

Growth going forward is expected to be rooted in rapid expansion of products to market – with this strategy being a key part of the company’s ability to maintain profitability. Primarily, this is due to its products being one-time solutions for end users. In other words, in order to sell more products, the company has to find different solutions for different users.

Looking at things from a technical perspective, and one of the few positives from the latest decline other than allowing us to get in at a discount, we have some well defined entry and exit parameters. For those looking long-term, an entry at current rates would likely be a hold until we at least gauge the implications of Fed actions before the end of the year. However, for a short to medium-term entry, current levels look attractive towards a well-defined target of aforementioned 2015 highs – just ahead of $29.

So to draw things to a close, Globus looks to present an interesting opportunity for the more optimistic investor looking to get in on what might be a short-term correction as part of a larger bull run. It also offers those unsure as to the current market conditions a chance of picking up a biotech exposure that is (to some extent, at least) insulated from wider global economic conditions. Keep in mind that picking up an allocation to any stock is risky at the moment – there’s so much uncertainty around that both fundamental and technical perspectives can quickly be proved wrong. Nobody could be blamed for being pretty much all in cash at the moment. However, for those that are not, this one’s well worth a look.

More from Market Exclusive:

  1. What Is the Real Cost of AstraZeneca’s Eye Cancer Flop?
  2. Frost Closes SciVac Deal, A Potential Blockbuster Lineup in Hepatitis?

  3. AstraZeneca Might Just Have Tapped Into 90% of a $13BB Market

Story continues below

Market Wrap Up – The Cat is Dead

By
TradeCircle
-
Dead Cat Bounce

Volatility continues. After a 3% bounce on the S&P 500 (NYSEARCA:SPY) and a very respectable 3.6% bounce on the Nasdaq (NASDAQ:QQQ), the dead cat bounce that was today ran out of spring.

It was once again the final minutes of trading that did the rally in, as the Dow Jones Industrial Average (NYSEARCA:DIA) crashed 3.3% in the final hour. It appears short selling traders are getting an early Christmas.

Oil also made a respectable comeback today, rising close to 2%, though oil stocks still saw the pain of the final hour collapse, as Exxon Mobil (NYSE:XOM) lost close to 4 percent into the close. Gold (NYSEARCA:GLD) and precious metals on the other hand did not respond positively to the sudden volatility at the end of the day, with the gold price ending the day down 1.2%.

All eyes will be on China (NYSEARCA:FXI) tonight, as trading opens in Shanghai in a few hours. The Nikkei had an equally volatile day yesterday preceding US market open, trading in a range of over 6% and ending down 4%. If the recent patterns continue, we should see a rise in the Euro (NYSEARCA:FXE) and corresponding fall in the US Dollar (NYSEARCA:UUP) along with a general collapse of emerging market currencies in the next 24 hours.

Finally, bonds got hammered today despite the negative close in equities. The iShares 20+ Year Treasury Bond ETF (NYSEARCA:TLT) is down 3.6% since its highs yesterday.

Given another poor close, look for stocks to open tomorrow gap down, and pressure on the Federal Reserve to call off any rate hikes to increase.

Story continues below

There Are Two Sides To The Market Crash Coin

By
Jennifer Aldershot
-
StockMarketCrash

As we addressed in this article, the floor fell out of global stock markets on Monday. Spurred by an equities market crash in China, UK and then US markets opened into decline. Some of the major indices recovered throughout the latter half of the day to register only single digit percentage overall declines – the Dow Jones Industrial Average (INDEXDJX:.DJI), FTSE 100 (INDEXFTSE:UKX) and the NASDAQ Composite (INDEXNASDAQ:.IXIC) – but the slide has no-doubt ravaged individual portfolios. Further, a slide into yesterday’s close in the US suggests we will open into further weakness this morning. The question now, is will this be looked back upon as the beginning of a longer-term bear market, or is it merely an (albeit) severe short-term correction. Additionally, if the latter of these two proves the case, is there a buying opportunity to be taken? Let’s have a look.

First, let’s consider the argument for a longer-term downturn. Basically, China has looked like it is in some trouble for at least the last few months, and probably more. Growth is down – as low as 4% by some estimates – and both individual and private appetite for taking on debt is almost non-existent. The Chinese government has taken some drastic measures recently to try and avoid yesterday’s collapse, including halting trading and devaluing its currency, but so far these measures have proven futile. So why is it such a big deal if China slows? Well, China is a large-scale exporter, but also imports heavily. However, in a bid to balance trade, the Chinese government has leaned towards reducing imports and increasing exports over the last 12 months. This was one of the primary drivers behind the devaluation of the yuan we saw earlier this year. This shift has led to some big changes in import revenues for key developing trade regions globally, however. This year alone, Chinese imports from the EU have declined nearly 13%. From Australia, more than 25%. Additionally, many developed nations and the vast majority of Asian nations rely heavily on Chinese demand for their commodities. South Africa has seen a 40% dip in its exports to China over the last six months. It is this sort of global withdrawal of resource driven capital that can filter through to wider negative implications.

However, of course, there is also an argument for the opposite situation. News media has also widely reported over the last few weeks that the US Fed could be looking to hike its base rate at the end of September. The implications of this are double edged – first that it allows the US to regain some element of control of its current monetary situation. Second, that higher borrowing costs could cripple already weak growth. The fact that this Chinese (and wider) equities market decline has happened now may be the factor that forces the Fed to change its mind. Elsewhere, the situation is similar. Japan, the UK and Europe are all looking at tightening monetary policy near term (i.e. before the end of the year) and this current situation may translate to a global period of extended loose policy. We are already overheated in major markets, so this is a dangerous approach as we are suggesting a reflation of what are already bubble proportions in many industries – but from a medium term profiteering perspective – is this such a big deal? Longer term, yes. Near term, all it means is there may still be some of the ride left in the latest bull market. Of course, the trick will be knowing when to get off. As yesterday’s action shows, things can turn around quicker than we thought possible.

So that’s where things stand. We could be headed for the next recession regardless of response, but there is a chance that the US interest rate hike has the potential to be the deciding factor in medium term global conditions. In other words, let’s see what Yellen does. At this point, her response looks more important than the short term participant response to an equities market crash.

 

Story continues below
1...14,61914,62014,621...14,628Page 14,620 of 14,628

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© Market Exclusive 2019